Has Andrew Anzeljc, MD received payments from drug or device companies?

Yes. Drug and device makers reported $12,839 in general payments to Andrew Anzeljc, MD across 122 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andrew Anzeljc, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andrew Anzeljc, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andrew Anzeljc, MD

Ophthalmic Plastic and Reconstructive Surgery · Knoxville, TNNPI 1891061396

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,200 of the $12,839 with a category attached, or 71.7%. Amgen accounts for 77.7% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $8,026 and has fallen 89.9% since, to $808 in 2025.

$12,839in general payments, 2019–2025

Across 122 payments — averaging $105.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$10K
Tarsus Pharmaceuticals, Inc.$392
Merz North America, Inc.$319
Mallinckrodt Hospital Products Inc.$285
Alcon$231
AbbVie$179
plus $1K from 20 others

$38,257in research payments, 2019–2025

Across 1 payment — averaging $38,257 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$38K

What the payments were for

Speaking & faculty fees$9,20072%
Food & beverage$3,63928%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	36	$9,982
Tarsus Pharmaceuticals, Inc.	16	$392
Merz North America, Inc.	3	$319
Mallinckrodt Hospital Products Inc.	14	$285
Alcon	6	$231
AbbVie(2 entities)	4	$179
Regeneron	2	$160
Rxsight Inc	1	$154
Johnson & Johnson Surgical Vision, Inc.	2	$148
Biotissue Holdings Inc.	6	$132
Novartis	4	$126
Astellas Pharma Global Development	1	$92
Genentech USA, Inc.	5	$85
Eyepoint US, Inc.	1	$83
Genentech, Inc.	1	$80
Bausch & Lomb, A Division Of Bausch Health US, LLC	4	$72
Sun Pharmaceutical Industries Inc.	4	$70
Stryker	1	$53
Bausch & Lomb Americas Inc.	2	$36
Kala Pharmaceuticals, Inc.	2	$33
Aerie Pharmaceuticals, Inc.	2	$30
Harrow Eye, LLC	1	$28
Dompe US, Inc.	1	$20
Sight Sciences, Inc.	1	$19
Shire North American Group Inc	1	$16
Integra Lifesciences Corporation	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TEPEZZA$9,200
LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$154
Tecnis IOL$125
Rocklatan$122
Rhopressa$122
XDEMVY$122

How this compares

Too few ophthalmic plastic and reconstructive surgery providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$418,252

Medicare patients

887

Services billed

8,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	822	$9,937
ErythromycinErythromycin Base	169	$1,849
Prednisolone Acetate	27	$714
Doxycycline Hyclate	46	$473
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	55	$135

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Knoxville

Stanley PaceKnoxville$1K
Andrew MeadorNashville$94K
Rex YannisChattanooga$19K
Michelle NguyenFranklin$645
Trey PegramClarksville$583
Ralph WesleyNashville$270
Kimberly KlippensteinNashville$212

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →